Barclays PLC Sells 1,557 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Barclays PLC lowered its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 3.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,419 shares of the medical research company's stock after selling 1,557 shares during the period. Barclays PLC owned about 0.14% of Bio-Rad Laboratories worth $13,278,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Venturi Wealth Management LLC grew its position in Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock worth $30,000 after purchasing an additional 87 shares in the last quarter. Picton Mahoney Asset Management boosted its stake in shares of Bio-Rad Laboratories by 55.6% in the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after buying an additional 35 shares during the last quarter. Asset Planning Inc bought a new position in shares of Bio-Rad Laboratories in the fourth quarter valued at approximately $33,000. UMB Bank n.a. increased its position in shares of Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after acquiring an additional 32 shares during the last quarter. Finally, Cape Investment Advisory Inc. bought a new stake in Bio-Rad Laboratories during the fourth quarter worth $38,000. 65.24% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Wells Fargo & Company decreased their target price on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. StockNews.com downgraded shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Monday, February 17th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $380.20.

Bio-Rad Laboratories Stock Performance

BIO traded up $4.57 during trading hours on Wednesday, hitting $249.55. The stock had a trading volume of 272,444 shares, compared to its average volume of 317,655. Bio-Rad Laboratories, Inc. has a 1 year low of $215.38 and a 1 year high of $387.99. The company's fifty day simple moving average is $252.93 and its 200 day simple moving average is $310.21. The stock has a market cap of $6.99 billion, a PE ratio of -3.84 and a beta of 1.12. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.